| Jimmy Muchechetere, Research Analyst at Investec Wealth & Investment, discusses his views about the latest medical advancement; gene editing. The article was originally published in Vision 2017, highlighting the thoughts of our Research Team, detailing some of the key investment themes they feel will be prevalent in 2017.
Download the full Vision 2017 eBook for free here: https://marketing.investec.com/vision-2017/ Since the successful sequencing of the human genome in 2003 the understanding of biology and pathophysiology has advanced the knowledge and utility of many existing fields. As a result there has been an explosion of new techniques to diagnose, prevent and treat pathologies. This singular event has also led to the spawning of new fields such as gene editing, a disruptive emerging technology that has the potential to change the way we view genetic or gene-related diseases, turning many from being lethal to chronic at worst and curable at best. |
Investec is a distinctive Specialist Bank and Asset Manager.
We provide a diverse range of financial products and services to a niche client base in three principal markets, the United Kingdom, South Africa and Australia, as well as certain other geographies.
Investec’s strategic goals are motivated by the desire to develop an efficient and integrated business on an international scale through the active pursuit of clearly established core competencies in the group’s principal business areas.
Tags:
